- Home
- NMS vs CRVO Comparison
NMS vs CRVO Comparison
Compare NMS & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- CRVO
- Stock Information
- Founded
- NMS 1993
- CRVO 2001
- Country
- NMS United States
- CRVO United States
- Employees
- NMS N/A
- CRVO N/A
- Industry
- NMS Finance Companies
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- NMS Finance
- CRVO Health Care
- Exchange
- NMS Nasdaq
- CRVO Nasdaq
- Market Cap
- NMS 71.2M
- CRVO 71.1M
- IPO Year
- NMS N/A
- CRVO N/A
- Fundamental
- Price
- NMS $11.91
- CRVO $9.09
- Analyst Decision
- NMS
- CRVO Strong Buy
- Analyst Count
- NMS 0
- CRVO 6
- Target Price
- NMS N/A
- CRVO $21.50
- AVG Volume (30 Days)
- NMS 12.0K
- CRVO 77.3K
- Earning Date
- NMS 01-01-0001
- CRVO 11-10-2025
- Dividend Yield
- NMS 4.11%
- CRVO N/A
- EPS Growth
- NMS N/A
- CRVO N/A
- EPS
- NMS N/A
- CRVO N/A
- Revenue
- NMS N/A
- CRVO $6,159,786.00
- Revenue This Year
- NMS N/A
- CRVO N/A
- Revenue Next Year
- NMS N/A
- CRVO N/A
- P/E Ratio
- NMS N/A
- CRVO N/A
- Revenue Growth
- NMS N/A
- CRVO N/A
- 52 Week Low
- NMS $9.21
- CRVO $1.80
- 52 Week High
- NMS $12.18
- CRVO $16.94
- Technical
- Relative Strength Index (RSI)
- NMS 49.57
- CRVO 70.21
- Support Level
- NMS $11.91
- CRVO $7.51
- Resistance Level
- NMS $12.04
- CRVO $9.45
- Average True Range (ATR)
- NMS 0.10
- CRVO 0.60
- MACD
- NMS -0.01
- CRVO 0.26
- Stochastic Oscillator
- NMS 35.62
- CRVO 91.86
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.